Supply Chains for Cell & Gene Therapies: Orchestrating a Successful Launch & Beyond

20/10/22

Advanced Therapy Medicinal Products (ATMPs), also known as cell and gene therapies, are becoming increasingly common.  However, they’re far more complex than “traditional” biotech products, with sophisticated requirements throughout their supply chains.  This webinar will:

• Identify the unique components that make ATMP supply chains so complex
• Show key points where precise orchestration is needed to prepare supply chains for launch and keep them running smoothly
• Provide guidance for decision makers, who must orchestrate supply chains in an environment with evolving regulatory frameworks and few consistent standards

• Ronald van Zitteren, Principal, AIM

• Laurent Goux
  Senior Vice President and General Manager, Europe, Krystal Biotech, Inc.
• Reinout Hesselink, Ph.D., R.H
  Cell Therapy Consulting
• David Kann
  Senior Associate, AIM

More information & registration

Please go to the website.